Walleye Capital’s Viridian Therapeutics VRDN Stock Holding History

Walleye Capital’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-200	Closed	-$6.22K	–	5036
2025 Q4	$6.22K	Hold	200	–	–	﹤0.01%	4326
2025 Q3	$4.32K	Buy	+200	New	+$3.61K	﹤0.01%	4325
2024 Q2	–	Sell	-3,600	Closed	-$63K	–	6050
2024 Q1	$63K	Sell	3,600 -2,000	-36%	-$38.8K	﹤0.01%	4595
2023 Q4	$122K	Buy	5,600 +5,100	+1,020%	+$80.5K	﹤0.01%	3962
2023 Q3	$7.67K	Buy	500 +200	+67%	+$3.81K	﹤0.01%	4520
2023 Q2	$7.14K	Sell	300 -4,600	-94%	-$118K	﹤0.01%	3970
2023 Q1	$125K	Buy	4,900 +2,000	+69%	+$64.1K	﹤0.01%	2800
2022 Q4	$84.7K	Buy	2,900 +1,400	+93%	+$32.3K	﹤0.01%	2408
2022 Q3	$31K	Buy	+1,500	New	+$27K	﹤0.01%	2668

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Walleye Capital's VRDN Position: Q1 2026 in Review

Walleye Capital reduced its Viridian Therapeutics (VRDN) stake by 11% in Q1 2026, selling an estimated $191K and leaving 54,398 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2023.

Walleye Capital first reported a position in VRDN in Q3 2021 and has held it in 19 quarters since. The position peaked at $12.7M in Q3 2024. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

Walleye Capital held 54,398 shares of Viridian Therapeutics worth $1.06M as of Q1 2026.
Walleye Capital sold 6,444 Viridian Therapeutics shares in Q1 2026, an estimated $191K.
Viridian Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2023 holding.
Walleye Capital first reported a position in Viridian Therapeutics in Q3 2021 and has held it in 19 quarters since.
Walleye Capital's Viridian Therapeutics position peaked at $12.7M in Q3 2024.
225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.